Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male aged 19 to 55 years at the screening~* Subject with BMI between 19 kg/m2 and 28 kg/m2 (inclusive)~* Subject who is able to participate in the whole study process~* Subject who provided written informed consent voluntarily after being fully informed of the study objectives, procedures and the investigational product~Exclusion Criteria:~* Subject who has a medical history of gastrointestinal, cardiovascular, respiratory, hepatobiliary, hematologic/oncologic, neuropsychologic, endocrinological, immunologic or renal disease that may be aggravated by the investigational product~* Subject with a systolic blood pressure of equal to or greater than 140 or less than 90 mmHg or with a diastolic blood pressure of equal to or greater than 90 or less than 60 mmHg~* Subject who has allergic disease that needs to be treated~* Subject with a history of drug allergies to any ingredient of the investigational product or marketed drug~* Subject with a blood hemoglobin value less than 13 g/dL or more than 17 g/dL~* Subject with a blood reticulocyte value more than the upper reference limit~* Subject with a blood vitamin B12 or ferritin or transferrin value less than the lower reference limit~* Subject with any non-negative results in blood serology (HBV, HCV, HIV, RPR) tests and in an examination of syphilis~* Subject who smokes more than 10 cigarettes per day~* Subject who consumes alcohol more than 140 g per week~* Subject with a history of drug abuse~* Subject who was administered with any investigational product, erythropoietin or iron supplement within 60 days prior to the screening~* Subject who donated whole blood within 60 days or blood components within 30 days prior to the screening~* Subject who took any herbal medicine within 30 days or any prescription drug within 14 days or over-the-counter drug considered to affect study within 10 days prior to the screening~* Subject who does not agree to use medically acceptable methods of contraception or who has plan to provide sperm during the study period~* Subject whom the investigator determined to have clinically significant findings in ECG~* Subject whose liver function is decreased with an AST, ALT or bilirubin value more than 1.5 times the upper reference limit~* Subject whose renal function is decreased with a GFR value calculated using MDRD equation less than the lower reference limit~* Subject whom the investigator determined to have clinically significant findings in clinical laboratory test~* Subject who is inappropriate as a subject of this study by the investigator's decision

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CJ-40001 (Type: EXPERIMENTAL): CJ-40001 60ug SC, IV injection
- NESP (Type: ACTIVE_COMPARATOR): NESP 60ug SC, IV injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete